Dare Bioscience Investor Presentation Deck slide image

Dare Bioscience Investor Presentation Deck

Statistically significant increases in Vaginal Pulse Amplitude (VPA)¹ Pfizer VPA Clinical Lab Study - Oral Viagra Vaginal Pulse Amplitude (mv) Oral Sildenafil provided a compelling proof of concept for FSAD Mean and Maximum VPA+ 5 P=0.093 Mean (Erotic) Placebo + Twelve healthy premenopausal women were studied. Oral Viagra P<0.05 Maximum (Erotic) Statistically significant improvement in genital stimulation (FIEI)² Pfizer Clinical Field Study - Oral Viagra Observed Number Improved (%) Improvement on FIEI Questionst 70 60 50 40 30 20 10 0 P=0.017 Question 2 Placebo Oral Viagra® P=0.015 Question 4 + Question #2 - "After taking study medication, the sensation/feeling in my genital (vaginal, labia, clitoris) area during intercourse or stimulation (foreplay) seemed to be: (a) more than before, (b) less than before, or (c) unchanged". 1. The Enhancement of Vaginal Vasocongestion by Sildenafil in Healthy Premenopausal Women. Journal of Women's Health & Gender-Based Medicine. Vol. 11, No. 4. 2002 2.Safety and Efficacy of Sildenafil Citrate for the Treatment of FSAD: A Double-Blind, Placebo Controlled Study. The Journal of Urology. Vol 170, 2333-2338, December 2003. Question #4 - "After taking the study medication, intercourse and/or foreplay was: (a) pleasant and satisfying; better than before taking the study medication, (b) unpleasant; worse than before taking study medication, (c) unchanged; no difference, or (d) pleasant; but still not like it used to be or I would like it to be." 202 postmenopausal women with FSAD who had protocol specified estradiol and free testosterone concentrations, and/or were receiving estrogen and/or androgen replacement therapy were studied. Key Takeaways of Viagra® studies: •Increased blood flow and clinical efficacy observed with oral sildenafil (Viagra®) in women. •The side effect profile of the oral formulation was not optimal for women - leading to the exploration of alternative delivery options including a topical route of administration. 35 I
View entire presentation